[go: up one dir, main page]

WO1990009182A1 - Composes pharmaceutiques et veterinaires destines aux traitement ou a la prevention de l'helminthiase - Google Patents

Composes pharmaceutiques et veterinaires destines aux traitement ou a la prevention de l'helminthiase Download PDF

Info

Publication number
WO1990009182A1
WO1990009182A1 PCT/GB1990/000204 GB9000204W WO9009182A1 WO 1990009182 A1 WO1990009182 A1 WO 1990009182A1 GB 9000204 W GB9000204 W GB 9000204W WO 9009182 A1 WO9009182 A1 WO 9009182A1
Authority
WO
WIPO (PCT)
Prior art keywords
iron
anthelmintic
composition according
complex
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1990/000204
Other languages
English (en)
Inventor
Iwan Euryn Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fisons Ltd
Original Assignee
Fisons Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fisons Ltd filed Critical Fisons Ltd
Priority to BR909005081A priority Critical patent/BR9005081A/pt
Publication of WO1990009182A1 publication Critical patent/WO1990009182A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Definitions

  • This invention relates to novel pharmaceutical and veterinary compositions for the treatment or prevention of helminthiasis, more particularly to such compositions comprising iron and an anthelmintic.
  • Helminthiasis is a major problem in many parts of the world, affecting both animals and humans. In poorer countries, infestation of humans and livestock with Q helminths aggravates shortages of food by increasing the nutritional demand of the host.
  • anthelmintic compounds are known. These have proved effective in the treatment of helminthiasis, but anthelmintic resistance in helminths is a growing 5 problem. This can be combatted by use of new anthelmintic compounds, but the research needed to identify or synthesise novel anthelmintic compounds is both expensive and time-consuming.
  • a pharmaceutical or veterinary composition comprising iron and an anthelmintic.
  • the iron is preferably present in the form of an iron-carbohydrate complex.
  • Iron-carbohydrate complexes which may be mentioned include iron-dextran complexes and iron-dextrin complexes, for example ferric hydroxide-dextran complex, ferric hydroxide-dextran heptonic acid complex and ferric hydroxide-dextrin heptonic acid complex.
  • ferric hydroxide-dextran heptonic acid complex Of particular interest is ferric hydroxide-dextran heptonic acid complex.
  • Ferric hydroxide-dextran heptonic acid complex and ferric hydroxide-dextrin heptonic acid complex were disclosed in UK Patent 1183940.
  • Suitable anthelmintics include benzimidazole derivatives, for example oxfendazole, albendazole, thiabendazole, parbendazole, mebendazole, fenbendazole and thiophanate; imidazothiazole derivatives, for example levamisole, pyrantel and morantel; avermectins, for example ivermectin; piperazines, for example piperazine citrate; anilids and substituted phenols; and organophosphates.
  • benzimidazole derivatives for example oxfendazole, albendazole, thiabendazole, parbendazole, mebendazole, fenbendazole and thiophanate
  • imidazothiazole derivatives for example levamisole, pyrantel and morantel
  • avermectins for example ivermectin
  • piperazines for example piperazine citrate
  • compositions according to the invention may be administered to mammals including pigs, sheep, horses, cattle and humans.
  • the preferred dosages of the active ingredients will vary with the nature of the preparation used and the mammal to which the composition is administered. For example, a 1.5ml injection comprising 20% by weight of ferric hydroxide-dextran heptonic acid complex containing 300mg of iron in an aqueous dispersion may be administered to a lamb of about 3 weeks of age, whereas a similar 10ml injection containing 2g of iron may be administered to a human.
  • the dosage of the anthelmintic is preferably within the normal dosage for the compound concerned, for example a 1.5ml injection may contain 7.5% by weight of leyamisole for a lamb of about 3 weeks of age.
  • a unit dose of the composition to provide from 0.5 to 50mg, more preferably 1 to 25mg, of anthelmintic per kg of body weight; and from 0.5 to lOOOmg, more preferably 10 to lOOmg, of iron per kg of body weight.
  • the composition of the invention may be administered orally (for example as a drench to animals) or by injection (intravenous or intramuscular) . In either case we prefer the composition to be in the form of an aqueous dispersion.
  • dispenser we mean a colloidal dispersion, a suspension or a solution, depending ⁇ upon the solubility of the materials to be dispersed in the aqueous phase.
  • the active ingredients may be worked up with inorganic or organic pharmaceutically or veterinarily acceptable adjuvants, carriers or excipients.
  • adjuvants, carriers or excipients are: for tablets and dragees: diluents, for example lactose; binders, for example cellulosic materials such as microcrystalline cellulose and methyl cellulose; disintegrating agents, for example starches such as maize starch; stabilisers, for example to prevent hydrolysis of the active ingredients; flavouring agents, for example sugars; fillers; stearates; and inorganic diluents, for example talc; for syrups, suspensions, dispersions, solutions and drenches: a liquid vehicle in which the active ingredients may be dissolved or suspended, for example water; and suspending agents, for example cellulose derivatives and gums.
  • Drenches may be administered with a drenching gun or bottle or a similar device adapted to administer a metered dose to an animal.
  • the drench may be supplied in the form of a wettable powder which can be dissolved or dispersed in water by a user.
  • a powder may comprise the active ingredient, a colloid to make a drench of suitable viscosity for the gun, and a surface active agent to assist in dispersion or dissolution of the powder in water.
  • the drench may also be supplied in li-quid form in which case it is desirable to incorporate a preservative such as glycerin or sodium benzoate; for hard or soft capsules: diluents, eg lactose; glidants, for example stearates; inorganic materials, for example silica or talc; stabilisers; and dispersing agents.
  • a preservative such as glycerin or sodium benzoate
  • diluents eg lactose
  • glidants for example stearates
  • inorganic materials for example silica or talc
  • stabilisers for example silica or talc
  • compositions may also contain further adjuvants, for example a composition for use in a tablet may contain lubricants and glidants to assist in tabletting, for example magnesium stearate, or wetting agents to assist in granulation, eg dioctyl sodium sulphosuccinate.
  • a composition for use in a tablet may contain lubricants and glidants to assist in tabletting, for example magnesium stearate, or wetting agents to assist in granulation, eg dioctyl sodium sulphosuccinate.
  • the composition may also, if desired, contain pharmaceutically or veterinarily acceptable dyes or colourants, and may, if desired, be coated using conventional film or sugar coating techniques.
  • the composition may also be in the form of a slow release formulation, for example a sustained release bolus, injection or capsule.
  • a method of treatment which comprises administering an anthelmintic in conjunction with iron to a mammal infested with, or at risk of being infested with, helminths. This method of treatment could be executed by sequential administration of anthelmintic and then iron.
  • products containing an anthelmintic and iron as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of helminthiasis are provided.
  • we prefer to execute the method of treatment by administration of a composition according to the invention as this has the advantage of single administration resulting in a saving of time for the person carrying out the treatment, and less distress for the mammals being treated.
  • the overall efficacy of oxfendazole alone was 48.1%.
  • the overall efficacy of iron injection alone (day 21) was 4.7%.
  • the overall efficacy of simultaneous administration of oxfendazole and iron injection was 67.9%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composés pharmaceutiques et vétérinaires comprenant du fer et un anthelminthique présentent une activité améliorée de façon significative contre les helminthes dans les intestins d'animaux infectés par comparaison à l'administration d'un anthelminthique seul. On peut administrer les composés aux mammifères tels que les cochons, les moutons, les chevaux, le bétail et les humains.
PCT/GB1990/000204 1989-02-09 1990-02-09 Composes pharmaceutiques et veterinaires destines aux traitement ou a la prevention de l'helminthiase Ceased WO1990009182A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR909005081A BR9005081A (pt) 1989-02-09 1990-02-09 Composicao farmaceutica e veterinaria e processo para o tratamento ou prevencao de helmintiase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB89/02894.8 1989-02-09
GB898902894A GB8902894D0 (en) 1989-02-09 1989-02-09 Compositions

Publications (1)

Publication Number Publication Date
WO1990009182A1 true WO1990009182A1 (fr) 1990-08-23

Family

ID=10651388

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1990/000204 Ceased WO1990009182A1 (fr) 1989-02-09 1990-02-09 Composes pharmaceutiques et veterinaires destines aux traitement ou a la prevention de l'helminthiase

Country Status (5)

Country Link
JP (1) JPH03504506A (fr)
AU (1) AU5083690A (fr)
BR (1) BR9005081A (fr)
GB (1) GB8902894D0 (fr)
WO (1) WO1990009182A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19712493A1 (de) * 1997-03-25 1998-10-01 Univ Karlsruhe Pharmazeutische Zubereitung, enthaltend eine Eisen-Calcium-Polyolato-Verbindung und deren Verwendung
JP2014520188A (ja) * 2011-06-21 2014-08-21 ゼルム−ヴェルク ベルンブルク アクチエンゲゼルシャフト ヒドロキシエチル澱粉誘導体の製造方法
RU2629203C2 (ru) * 2016-02-18 2017-08-25 Федеральное государственное бюджетное научное учреждение "Прикаспийский зональный научно-исследовательский ветеринарный институт" Антигельминтное средство для лечения и профилактики делафондиоза, альфортиоза, оксиуроза, стронгилеза и трихонематидозов лошадей
US11123321B2 (en) 2002-10-23 2021-09-21 Vifor (International) Ag Aqueous iron carbohydrate complexes, their production and medicaments containing them
US11344568B2 (en) 2006-01-06 2022-05-31 American Regent, Inc. Methods and compositions for administration of iron
CN116726045A (zh) * 2023-06-30 2023-09-12 重庆汉佩生物科技有限公司 一种氟雷拉纳组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 80, No. 9, 4 March 1974, (Columbus, Ohio, US), H.H. VEGORS: "Effect of Intramuscular Injections of Iron-Dextran on Ovine Haemonchosis", see page 27* Abstract 44072f, & Proc. Helminthol. Soc. Wash. 1973, 40 (1), 66-9* *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19712493A1 (de) * 1997-03-25 1998-10-01 Univ Karlsruhe Pharmazeutische Zubereitung, enthaltend eine Eisen-Calcium-Polyolato-Verbindung und deren Verwendung
US11123321B2 (en) 2002-10-23 2021-09-21 Vifor (International) Ag Aqueous iron carbohydrate complexes, their production and medicaments containing them
US11590097B2 (en) 2002-10-23 2023-02-28 Vifor (International) Ag Aqueous iron carbohydrate complexes, their production and medicaments containing them
US11433091B2 (en) 2006-01-06 2022-09-06 American Regent, Inc. Methods and compositions for administration of iron
US11344568B2 (en) 2006-01-06 2022-05-31 American Regent, Inc. Methods and compositions for administration of iron
US11364260B2 (en) 2006-01-06 2022-06-21 American Regent, Inc. Methods and compositions for administration of iron
US11406656B2 (en) 2006-01-06 2022-08-09 American Regent, Inc. Methods and compositions for administration of iron
US11478502B2 (en) 2006-01-06 2022-10-25 American Regent, Inc. Methods and compositions for administration of iron
US12329772B2 (en) 2006-01-06 2025-06-17 American Regent, Inc. Methods and compositions for administration of iron
JP2018100424A (ja) * 2011-06-21 2018-06-28 ゼルムヴェルク ベルンブルク アクチエンゲゼルシャフトＳｅｒｕｍｗｅｒｋ Ｂｅｒｎｂｕｒｇ Ａｇ ヒドロキシエチル澱粉誘導体の製造方法
US9631032B2 (en) 2011-06-21 2017-04-25 Serumwek Bernburg AG Method for manufacturing hydroxyethyl starch derivatives
JP2014520188A (ja) * 2011-06-21 2014-08-21 ゼルム−ヴェルク ベルンブルク アクチエンゲゼルシャフト ヒドロキシエチル澱粉誘導体の製造方法
RU2629203C2 (ru) * 2016-02-18 2017-08-25 Федеральное государственное бюджетное научное учреждение "Прикаспийский зональный научно-исследовательский ветеринарный институт" Антигельминтное средство для лечения и профилактики делафондиоза, альфортиоза, оксиуроза, стронгилеза и трихонематидозов лошадей
CN116726045A (zh) * 2023-06-30 2023-09-12 重庆汉佩生物科技有限公司 一种氟雷拉纳组合物
CN116726045B (zh) * 2023-06-30 2024-03-19 重庆汉佩生物科技有限公司 一种氟雷拉纳组合物

Also Published As

Publication number Publication date
GB8902894D0 (en) 1989-03-30
BR9005081A (pt) 1991-08-06
JPH03504506A (ja) 1991-10-03
AU5083690A (en) 1990-09-05

Similar Documents

Publication Publication Date Title
KR101585584B1 (ko) 아레나바이러스 감염을 치료하기 위한 항바이러스 약물
US7396820B2 (en) Anthelmintic formulations
EP0820281B1 (fr) Composition pharmaceutique contenant des n-chlorophenylcarbamates et des n-chlorophenylthiocarbamates pour inhiber la croissance des virus
WO2011054068A1 (fr) Combinaisons pharmaceutiques, compositions pharmaceutiques, médicament et méthode pour le traitement d'animaux
JP2019167358A (ja) 魚介類の微胞子虫の防除用組成物及びそれを用いた魚介類の微胞子虫の防除方法
US4058620A (en) Therapeutic agents for improving cardiovascular function
WO1990009182A1 (fr) Composes pharmaceutiques et veterinaires destines aux traitement ou a la prevention de l'helminthiase
CN101011408A (zh) 一种治疗畜禽体内外寄生虫病的兽用复方制剂及其制备工艺
US4076834A (en) Therapeutic agents for improving cardiovascular function
EP0710105A4 (fr) Compositions anthelmintiques synergiques
US3991209A (en) Halomethanesulfonamides for eradicating internal parasites
Marriner et al. Nematode infections of domestic animals: gastrointestinal infections
US3978060A (en) Method of eradicating internal parasites
JP2000204037A (ja) 筋萎縮性側索硬化症治療薬
EP0407405A1 (fr) Procede pour traiter l'echauffement de la fourchette et de la putrefaction du sabot
WO2008038423A1 (fr) Composition antiphlogistique et analgésique pour une utilisation orale
US4584305A (en) Aiding the regression of neoplastic disease with 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole
US3958008A (en) Anthelmintic methods of use
Bardón et al. Evaluation by larval recovery of mebendazole activity in experimental murine toxocariasis
US4034110A (en) Anthelmintics effective against liver flukes
WO2005016356A1 (fr) Formulations anthelminthiques ameliorees
CN116549455B (zh) PLK4抑制剂Centrinone在制备治疗包虫病药物中的应用
US3303092A (en) 1-substituted 2, 6-dihalo phenyl hypnotic and analgesic
US3961068A (en) Use of ipronidazole in combatting Sphaerophorus necrophorus infections
US2793157A (en) Anticonvulsant 3-ethyl-5-phenyl hydantoin unit dosages and method of using same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1990903205

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1990903205

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: CA